Effect of Vitamin D Supplementation as Adjuvant Therapy in Neonatal Jaundice in Combination With Phototherapy

Neonatal jaundice frequently occur during initial week of life. Neonatal jaundice is one of the leading causes of hospital admission and readmission. Some studies have suggested that the healthy newborns with hyperbilirubinemia outside the physiological range have notably reduced serum vitamin D levels. This deficiency is inversely associated with neonatal hyperbilirubinemia, suggesting that low vitamin D levels could be a potential risk factor for jaundice among neonates.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Neonatal Jaundice Congenital, Hereditary, and Neonatal Diseases and Abnormalities Hyperbilirubinemia Hyperbilirubinemia, Neonatal Infant, Newborn, Diseases Jaundice, Neonatal Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

3 day–28 day

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Pediatric Medicine Department University of Child Health Sciences, Children's Hospital Lahore

Lahore, Pakistan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Both genders
Admitted between 3-28 days of age.
Indirect hyperbilirubinemia with TSB levels between 14-20 mg/dL
Born via either cesarean or vaginal delivery
Birth weight greater than 2500 grams

Exclusion criteria

Prior phototherapy treatment
Preterm birth (gestational age below 37 weeks).
SpO2 < 95% at the time of admission
Severe respiratory distress or failure
Neonatal sepsis
Congenital anomalies
Parents/guardians unwilling to let their neonates be part of this study.

Treatment and study plan

Vitamin D

Drug

Vitamin D supplementation as vitamin D, 2 drops i.e., 800 IU daily for 5 days.

Primary outcomes

Total Serum bilirubin levels

Time frame: 5 days

Total Serum bilirubin levels evaluated

Sponsors and collaborators

Lead sponsor

Muhammad Aamir Latif

Other

Registry information

Important dates

Study start: 2022
Primary completion: 2022
Study completion: 2022
First posted: Oct 21, 2024
Registry last updated: Oct 21, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed